weight loss
∙2 minute read
At Numan, we've always believed in a holistic approach to weight loss, combining medical treatments with behavioural changes and lifestyle support - and now, it's official. Our comprehensive 90-day retrospective study highlights just how effective this strategy can be.
Our study evaluated 2,366 patients who were treated with a dual GLP-1 and GIP agonist (tirzepatide), alongside support from health coaches via the interactive Numan app. The results highlight significant differences in the amount of weight loss based on the level of engagement with our programme.
Effectiveness of a combined approach:
Patients who used Numan’s mobile app and engaged with coaching saw significantly better results, losing an average of 11.3% of their weight, which is 50% more than those who did not interact with the Numan app and health coaches but used medication alone. This cohort achieved an average weight loss of 7.5%.
Enhanced weight loss with the app:
Even without coaching, participants who only used the Numan app alongside their medication achieved an average weight loss of 10.2%, significantly higher than the cohort who relied solely on medication.
Medication, Numan app, and coaching: 11.3% average weight loss
Medication and Numan app: 10.2% average weight loss
Medication only: 7.5% average weight loss
Overall, 63% of Numan participants exceeded the typical clinical trial results for Tirzepatide¹, with at least 9% body weight loss. Of these, 35% achieved more than 12% weight loss. These improved outcomes are likely due to the combination of using the app's tracking features and access to coaching support, which provides patients with the tools and guidance to maintain consistency and optimise their weight loss efforts.
Numan’s Weight Loss Programme is designed to provide comprehensive support beyond the medication. Here’s how our health coaches and app can help you go further on your weight loss journey.
Numan’s health coaches specialise in behavioural change, offering personalised guidance on exercise, nutrition, sleep, and mindset. They help patients transform their habits and achieve sustainable weight loss. The results from our study highlight the value of consistent, tailored support.
The Numan app enhances this support by providing progress tracking, seamless communication with your health coach, expert articles, medication reminders, and real-time chats with clinicians. Users who logged more than 30 app events within their first three months experienced superior weight loss results compared to those with lower app usage.
This combination of professional guidance and digital tools creates a care support system that significantly improves weight loss outcomes and overall health.
There have been amazing breakthroughs in weight loss medications, but they are not the complete solution. Our study shows that combining these medications with lifestyle support and behavioural change leads to significantly better outcomes.
The analysis included 2,366 participants who self-reported their weight using Numan's mobile app, web platform, or direct patient or clinician communication. Participants were evaluated for weight loss (percentage of initial body weight) over a 90-day period, with no participant experiencing a delivery gap of more than 40 days between medication doses.
Programme engagement thresholds:
Active app users: Defined as those logging a minimum of 30 app events (such as tracking weight, logging medication, or reading articles) within the first three months.
Engaged coaching participants: Defined as those sending at least 10 messages to a health coach within the first three months.
All participants were prescribed Tirzepatide (Mounjaro) and self-administered weekly subcutaneous injections. The injections were delivered to their homes every 28 days. The participants were divided into three groups based on their level of engagement with Numan’s app and coaching services:
Medication only: Participants received medication without using the app or coaching.
Medication and app: Participants used the app but did not engage with coaching. (Active app users).
Medication, app, and coaching: Participants used the app and actively engaged with coaching. (Active app users and engaged coaching participants).
Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M.C., and Stefanski, A., 2022. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), pp.205-216.
